EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PI3Kβ inhibition enhances ALK ‐inhibitor sensitivity in ALK ‐rearranged lung cancer

Sarang S Talwelkar, Mikko I Mäyränpää, Julia Schüler, Nora Linnavirta, Annabrita Hemmes, Simone Adinolfi, Matti Kankainen, Wolfgang Sommergruber, Anna-Liisa Levonen, Jari Räsänen, Aija Knuuttila, Emmy W Verschuren iD und 1 weitere

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Sarang S Talwelkar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Finland. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helsinki Institute of Life Science, Helsingin Yliopisto, Suomen Lääketieteen Säätiö, K. Albin Johanssons Stiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment with anaplastic lymphoma kinase (ALK) inhibitors significantly improves outcome for non‐small‐cell lung cancer (NSCLC) patients with ALK ‐rearranged tumors. However, clinical resistance typically develops over time and, in the majority of cases, resistance mechanisms are ALK‐independent. We generated tumor cell cultures from multiple regions of an ALK ‐rearranged clinical tumor specimen and deployed functional drug screens to identify modulators of ALK‐inhibitor response. This identified a role for PI3Kβ and EGFR inhibition in sensitizing the response regulating resistance to ALK inhibition. Inhibition of ALK elicited activation of EGFR, and subsequent MAPK and PI3K‐AKT pathway reactivation. Sensitivity to ALK targeting was enhanced by inhibition or knockdown of PI3Kβ. In ALK ‐rearranged primary cultures, the combined inhibition of ALK and PI3Kβ prevented the EGFR‐mediated ALK‐inhibitor resistance, and selectively targeted the cancer cells. The combinatorial effect was seen also in the background of TP53 mutations and in epithelial‐to‐mesenchymal transformed cells. In conclusion, combinatorial ALK‐ and PI3Kβ‐inhibitor treatment carries promise as a treatment for ALK ‐rearranged NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansPhosphatidylinositol 3-KinasesReceptor Protein-Tyrosine KinasesAnaplastic Lymphoma KinaseProtein Kinase InhibitorsErbB Receptors

Stichwörter der Autor:innen

ALK-rearranged lung cancerEGFREML4-ALKNSCLCPI3Kβcombination treatmentdrug resistancepatient-derived cells

Substanzen

Phosphatidylinositol 3-KinasesReceptor Protein-Tyrosine KinasesAnaplastic Lymphoma KinaseProtein Kinase InhibitorsErbB Receptors

Autor:innen und Institutionen

  • Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Finland.
  • Institute of Biomedicine and MediCity Research Laboratories, University of Turku, Finland.
  • Department of Pathology, Helsinki University Hospital and University of Helsinki, Finland.
  • Charles River Research Services, Germany GmbH, Freiburg im Breisgau, Germany.
  • A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
  • Cancer Cell Signalling, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

ORCID-Profile: Emmy W Verschuren, Krister Wennerberg

Förderung

  • Helsinki Institute of Life Science, Helsingin Yliopisto
  • Suomen Lääketieteen Säätiö
  • K. Albin Johanssons Stiftelse
  • Horizon 2020 Framework Programme
  • Novo Nordisk Fonden
  • Sigrid Juséliuksen Säätiö
  • Academy of Finland
  • Helsingin Yliopisto

Zitieren

APA

Talwelkar, S. S., Mäyränpää, M. I., Schüler, J., Linnavirta, N., Hemmes, A., Adinolfi, S., Kankainen, M., Sommergruber, W., Levonen, A. L., Räsänen, J., Knuuttila, A., Verschuren, E. W., & Wennerberg, K. (2023). PI3Kβ inhibition enhances ALK ‐inhibitor sensitivity in ALK ‐rearranged lung cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13342

Vancouver

Talwelkar SS, Mäyränpää MI, Schüler J, Linnavirta N, Hemmes A, Adinolfi S, et al. PI3Kβ inhibition enhances ALK ‐inhibitor sensitivity in ALK ‐rearranged lung cancer. Molecular Oncology. 2023. doi:10.1002/1878-0261.13342

BibTeX
@article{Talwelkar2023,
  author = {Talwelkar, Sarang S and Mäyränpää, Mikko I and Schüler, Julia and Linnavirta, Nora and Hemmes, Annabrita and Adinolfi, Simone and Kankainen, Matti and Sommergruber, Wolfgang and Levonen, Anna-Liisa and Räsänen, Jari and Knuuttila, Aija and Verschuren, Emmy W and Wennerberg, Krister},
  title = {PI3Kβ inhibition enhances ALK ‐inhibitor sensitivity in ALK ‐rearranged lung cancer},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13342}
}
Kostenlos starten →